TriangleZEN-3694 (NCT06922318)
ZEN-3694 trial for Metastatic Castration-resistant Prostate Cancer (NCT06922318). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for asymptomatic adult men with metastatic castration-resistant prostate adenocarcinoma progressing after an androgen-pathway inhibitor.
The idea: daily ZEN-3694 blocks BET proteins involved in growth-related gene expression. It is paired first with testosterone injections every four weeks. After scan-confirmed progression, testosterone stops, ZEN-3694 increases, and enzalutamide adds androgen-receptor blockade. Androgen deprivation continues unless surgically castrated. Biopsies are required when accessible. Researchers measure progression-free survival across this sequence against historical controls.
This phase 2 study plans 50 patients. Samuel Denmeade leads at Johns Hopkins, Baltimore, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.